甲酸IV抑制MAPK通路,并促进心力衰竭小鼠的线粒体自
Yaoyao Wang1, Yujiang Chen1, Tengxian Li1
1Department of Pathology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550000, China.
概括
阿斯特拉加索酸IV (AS-IV) 通过增强线粒体功能和线粒细胞衰竭来改善心力衰竭 (HF). 这种天然化合物通过抑制p38 MAPK通路来保护心脏损伤.
科学领域:
- 心血管生物学 心血管生物学
- 线粒体医学 线粒体医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一个主要的全球健康问题,与线粒体功能障碍和 mitoophagy 损害有关.
- 甲酸IV (AS-IV) 在高血压中,特别是关于线粒体平衡的治疗潜力在很大程度上尚未被探索.
研究的目的:
- 调查AS-IV对心力衰竭的老鼠模型中的线粒体功能和线粒体衰竭的影响.
- 阐明潜在的分子机制,包括MAPK通路的作用.
主要方法:
- 通过腹腔大动脉收缩建立了一种小鼠心力衰竭模型.
- 大鼠接受AS-IV (20 mg/kg和80 mg/kg) 的治疗.
- 评估了线粒体功能,纤维化,缩,自和MAPK通路激活.
主要成果:
- 治疗AS-IV显著降低了心肌纤维化和心肌缩.
- 观察到线粒体功能得到改善,ATP和超氧化物脱酶增加,活性氧物种减少,PGC-1α和TFAM上调.
- AS-IV增强了线粒体自和抑制了p38 MAPK通路的激活.
结论:
- AS-IV通过促进线粒体和维护线粒体功能来缓解心力衰竭.
- AS-IV的治疗作用包括抑制MAPK通路.
- AS-IV显示出作为心力衰竭的新型治疗剂的前景.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K